The dual STAT3/CDK2 inhibitor Nifuroxazide suppressed STAT3 phosphorylation, thereby blocking the release of Palbociclib-induced senescence-associated secretory phenotype (SASP) and alleviating SASP-mediated remodeling of the tumor microenvironment, metastasis, and drug resistance. This evidence concerns the gene STAT3 and neoplasm.